Repligen Announces Agreement with Navigo Proteins for the Exclusive Co-Development of Next Generation Affinity Ligands
WALTHAM, Mass., June 27, 2018 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced an agreement with Navigo Proteins GmbH (“Navigo”) for the advancement of exclusive novel affinity ligands used in monoclonal antibody (mAb) and non-mAb downstream purification processes. Under the terms of this agreement, Repligen and Navigo will co-develop a portfolio of next generation ligands, utilizing Navigo’s proprietary Precision Capturing™ technology platform. As part of the collaboration, Repligen receives intellectual property rights and exclusivity on all affinity ligands developed with Navigo, and Navigo receives a series of milestone and royalty payments.
This formal agreement expands on a two-year relationship between Repligen and Navigo that has produced a best-in-class Protein A ligand with strong caustic stability and ultra-high binding capacity. Scale-up and validation for
